Day One Biopharmaceuticals Inc

NASDAQ DAWN

Data sourced from iex and EODHD
Download Data

Day One Biopharmaceuticals Inc Income Statement 2020 - 2024

This table shows the Income Statement for Day One Biopharmaceuticals Inc going from 2020 until 2024. The income statement, also known as the profit and loss statement, is a financial statement that provides a summary of a company's revenues, expenses, and net income over a specific period (such as a quarter or a year). It shows the company's ability to generate revenue, manage expenses, and ultimately determine its profitability.
Income Statement Trend Unit 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31
Revenue
M 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Cost of Revenue
M 0 0 0 0 0 - - - - - - - - - - - -
Gross Profit
M 0 0 0 0 0 - - - - - - - - - - - -
Operating Expenses
M 67 60 51 49 46 - - - - - - - - - - - -
Selling, General, and Administrative Expenses (SG&A)
M 27 22 18 17 18 17 18 14 13 29 9 6 3 2 1 1 1
Research and Development (R&D) Expenses
M 40 37 33 32 28 26 22 23 15 44 10 10 13 4 3 1 1
Other Operating Expenses
M 0 0 0 0 0 - - - - - - - - - - - -
Costs and Expenses
M 67 59 51 49 46 - - - - - - - - - - - -
Operating Income
M -67 -60 -51 -49 -46 -43 -40 -37 -28 -122 -19 -15 -16 -6 -4 -2 -2
Interest Expense
M - 3 - - 3 3 2 0 0 0 0 0 0 0 0 0 0
Non-operating Income/Expense
M 4 5 5 3 3 3 2 0 0 2 0 0 0 -29 0 0 0
EBT
M -62 -55 -46 -46 -42 -40 -38 -37 -28 -120 -19 -15 -16 -36 -4 -2 -2
Income Tax Provision
M - 11 0 -3 -7 -5 -4 0 0 0 0 0 -1 -1 -1 -1 0
Income after Tax
M - -65 -46 -42 -35 -35 -34 -36 -28 -120 -19 -15 -15 -34 -3 -2 -2
Non-Controlling Interest
M - - 0 0 0 0 0 0 0 -200 0 99 -1 - -1 -1 0
Net Income
M - - -46 -46 -42 -40 -38 -37 -28 178 -19 -114 -15 - -3 -2 -2
Shares (Basic, Weighted)
M - - - - - - - - - - - - - - - - -
Shares (Diluted, Weighted)
R 86,679,282.00 79,773,004.00 85,952,501.00 74,964,878.00 71,972,888.00 65,466,773.00 71,008,993.00 60,760,527.00 58,382,444.00 36,960,569.00 57,514,218.00 22,661,889.00 60,337,415.00 42,030,978.00 42,030,978.00 42,030,978.00 42,030,978.00
EBITDA
M -67 -64 -51 -53 -49 -43 -40 -37 -28 -122 -19 -14 -16 -6 -4 -2 -2
Depreciation and Amortization
M 0 0 0 0 -3 0 0 0 0 0 0 0 0 0 0 0 0
EBIT
M -67 -65 -52 -53 -46 -43 -40 -37 -28 -122 -19 -14 -16 -6 -4 -2 -2
Income from Discontinued Operations
M - - - - - - - - - - - - - - - - -
Tax Rate (Effective)
% - -19.30 0.21 7.43 16.55 13.20 10.05 1.03 0.01 0.00 -0.04 0.17 5.71 3.49 26.29 26.53 22.89
Earnings Per Share (EPS), Basic
M - - - - - - - - - - - - - - - - -
Earnings Per Share (EPS), Diluted
M - - 0 0 0 0 0 0 0 0 0 0 0 - 0 0 0
Gross Profit Margin
% - 50.00 - - - - - - - - - - - - - - -
Operating Income Margin
% - -10,628.04 - - - - - - - - - - - - - - -
Net Income Margin
% - - - - - - - - - - - - - - - - -
EBITDA Ratio
% - -11,506.79 - - - - - - - - - - - - - - -
EBIT Ratio
% - -11,525.18 - - - - - - - - - - - - - - -
EBT Ratio
% - -9,734.11 - - - - - - - - - - - - - - -

StockViz Staff

September 16, 2024

Any question? Send us an email